AIM ImmunoTech Investor Relations Material

AIM ImmunoTech Inc., formerly known as Hemispherx Biopharma, Inc., is an immuno-pharmaceutical company dedicated to the research and development of therapeutics for the treatment of multiple types of cancers, viral diseases, and immune-deficiency disorders. The company's leading product candidate is Ampligen, a drug composed of macromolecular ribonucleic acid molecules aimed at treating chronic fatigue syndrome (CFS). Ampligen is also under development for various cancer types, including renal cell carcinoma, malignant melanoma, and others, as well as for conditions like Hepatitis B, HIV, COVID-19, and post-COVID conditions. Another key product is Alferon N Injection, an injectable formulation of natural alpha interferon for treating human papillomavirus (HPV) and genital warts. The company is headquartered in Ocala, Florida, and its shares are listed on the NYSE.